Pharmaceutical-grade hexamethyl disilazane (HMDS), CAS 999-97-3, molecular formula C₆H₁₉NSi₂, is supplied as a low-viscosity organosilicon liquid for surface capping and moisture-protective treatment in solid and parenteral manufacturing environments. The product designation “Hexamethyl Disilazane(HMDS) Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” does not correspond to a single harmonized model code; it is identified by CAS registry, pharmacopoeial test set, supplier lot code, and the manufacturer’s controlled raw material specification. A representative release specification includes gas chromatographic assay not less than 99.0% area percent under USP <621>, water content not more than 0.05% w/w by USP <921> Method Ia, residue on ignition not more than 0.01% by USP <281>, and elemental impurity limits aligned with ICH Q3D Option 1. The phrase “API grade” denotes documentation, residual solvent control, and cleaning validation alignment expected for active pharmaceutical ingredient manufacturing; it does not indicate that HMDS is a therapeutically active moiety.

For identification and container closure control, the material is confirmed by infrared spectrophotometry against a reference standard under USP <197> and by gas chromatographic retention time. The product is miscible with anhydrous aprotic solvents such as heptane and toluene; it reacts with water, alcohols, and other protic solvents, releasing ammonia. Pharmaceutical-grade lots are packaged in sealed HDPE or PTFE-lined steel drums under nitrogen headspace. Typical fill sizes for solid-dosage manufacturing sites are 25 L or 200 L, depending on batch throughput. The certificate of analysis includes residual solvent data under USP <467> and a statement of elemental impurity compliance with ICH Q3D when used at not more than 0.20% w/w of the granule mass.

Under dry nitrogen pressure, the liquid is transferred through 316L stainless steel lines with PTFE seals. The liquid has a density of 0.774 g/mL at 25°C measured by ASTM D4052-22, a boiling point of 126°C, a refractive index of 1.408 at 20°C, and a closed-cup flash point of 25°C; storage therefore follows flammable liquid handling procedures under GHS Category 3. Nitrogen blanketing, vessel grounding, and oxygen exclusion are used because the material hydrolyses on contact with atmospheric moisture, releasing ammonia and hexamethyldisiloxane. In granulation suites, the liquid is metered by corrosion-resistant positive-displacement or peristaltic pumps, and the feed line is purged after each batch with anhydrous heptane to prevent cross-batch carryover of hydrolysed residues. Transfer equipment is dedicated or cleaned with anhydrous heptane followed by nitrogen drying; residual water in a transfer line creates a localised loss of silylating capacity before the liquid reaches the granule bed.

Does Residual Water Content Alter Silylating Capacity in Fluid-Bed Granulation?

Residual water is the primary process variable controlling the molar availability of trimethylsilyl groups. Under anhydrous granulation conditions, one mole of water consumes one mole of HMDS via hydrolysis to hexamethyldisiloxane and ammonia: (CH₃)₃Si-NH-Si(CH₃)₃ + H₂O → (CH₃)₃Si-O-Si(CH₃)₃ + NH₃. When granule moisture is greater than 0.05% w/w by USP <921> Method Ia, the liquid feed demand increases because the hydrolysis reaction occurs before surface capping is complete. Fluid-bed dryers with inlet air dew point below −40°C and exhaust ammonia scrubbers are operated with real-time electrochemical ammonia detection; the scrubber discharge is interlocked at 25 ppm (8-hour TWA ACGIH TLV) to prevent operator exposure. Batch records require post-drying granule moisture of 0.20% to 0.50% w/w before HMDS exposure for hygroscopic APIs; shorter drying cycles leave adsorbed water that generates ammonia pockets and localised tablet surface defects.

In a fluid-bed bowl, the silylation reaction front is controlled by spray nozzle size and atomizing air pressure rather than by intrinsic kinetics. Nozzles with a mean droplet size of 5 µm to 15 µm are used to avoid localized over-wetting, and the liquid feed is stopped when the contact angle plateau is reached. The endpoint is confirmed by sampling granules from the product bowl and testing moisture uptake at 60% RH over 24 h; a mass gain of more than 1.0% indicates incomplete capping.

In tablet and capsule operations, the hydrophobic capping effect is evaluated by sessile drop contact angle on compacted ribbons. Untreated microcrystalline cellulose compacts commonly show contact angles below 50°; silanized compacts can exceed 100° when measured with an optical goniometer after 24 h conditioning at 40% RH. This shift reduces moisture uptake in hygroscopic granule formulations, but it also changes the lubrication requirement. Magnesium stearate blends with silanized granules may require adjustment of hydrophobic surface coverage before flow becomes stable; production-scale bin blending with a diffusion mixer at 10 rpm for 15 min is followed by sieve analysis at 125 µm to detect agglomerates. Published data for this specific HMDS granulation configuration is limited; the above ranges are implementation-specific rather than pharmacopoeial acceptance criteria.

After silanization, capsule filling requires adjustment of tamping pin settings because the angle of internal friction decreases. On a dosator-type capsule machine, bulk density changes of 0.05 g/mL to 0.10 g/mL have been observed after HMDS capping; the fill depth is reduced accordingly. For roller-compacted ribbons, the ribbon solid fraction before milling may increase by 0.02 to 0.04 because the hydrophobic surface reduces adhesion to the compaction rolls; this effect is machine-specific and is characterised during transfer-scale trials.

Pharmacopoeial Specifications for High-Purity Organosilicon Process Aids

The lot release profile for pharmaceutical-grade HMDS differs from technical-grade material primarily in chloride, water, and nonvolatile residue limits. The table lists a representative specification set compiled from supplier certificates of analysis aligned with USP, Ph. Eur., and ICH requirements. Values apply to the bulk liquid as supplied; in-use dilution, if performed, is validated with residue on ignition testing after forced evaporation.

For injectable and oral liquid manufacturing, pharmaceutical-grade HMDS is not added to the final dosage form as an active ingredient. It is used as a surface deactivation agent on borosilicate glass vials and closures before filling. The treatment deposits a trimethylsilyl monolayer that reduces nonspecific adsorption of peptide and protein drug candidates on Type I borosilicate glass. Vials are washed in a rotary vial washer, dried, and exposed to HMDS vapour under controlled humidity below 30% RH, followed by depyrogenation in a hot-air tunnel at 250°C to 350°C. This sequence converts residual silanol groups to trimethylsilyl ethers and removes ammonia by thermal stripping. The difference from industrial silanization is that the pharmaceutical process includes endotoxin control in the washing step and particulate matter verification according to USP <788> for the final container. Limitation: this surface treatment is not a substitute for validated container closure integrity testing, and the HMDS layer is not intended to support terminal sterilization beyond the vial’s normal thermal profile.

The silanization process for injectable vials is qualified with vapour-phase treatment rather than liquid immersion to reduce residual organosilicon droplets. A closed vapour chamber operating at 60°C to 80°C under dry nitrogen is used; the HMDS vapour pressure is sufficient to produce a monomolecular layer on glass. After vapour exposure, vials are rinsed with water for injection only if the intended drug product is sensitive to residual ammonia; otherwise thermal stripping is the preferred removal step. The final container is tested for extractables and leachables according to USP <1663> and USP <1664> when the product is a parenteral dosage form.

When Tablet Granule Surfaces Require Hydroxyl Capping Before Compression

Hydroxyl capping is implemented when a hygroscopic API or an amorphous solid dispersion shows sticky agglomeration during high-shear wet granulation. HMDS is introduced after the granule is dry and before lubrication, typically at 0.05% to 0.20% w/w relative to dry granule mass. The liquid is diluted with anhydrous heptane in a ratio of 1:5 to 1:10 to improve distribution across a twin-screw granulator with an L/D ratio of 25:1 to 40:1; the solvent is evaporated under vacuum at 40°C to 45°C to avoid thermal degradation of heat-sensitive actives. Compared with technical-grade HMDS, the pharmaceutical-grade material with chloride below 5 ppm reduces the risk of chloride-induced corrosion in 316L granulator barrels and avoids tablet discoloration in formulations containing metal-sensitive APIs. Process incompatibility: the addition of HMDS to wet granulation is avoided because the hydrolysis byproduct ammonia raises granule pH and can destabilize acid-labile drugs. For such acid-labile formulations, silane coupling agents are not interchangeable with HMDS without repeating forced degradation studies.

Compared with chlorotrimethylsilane, HMDS generates ammonia rather than hydrogen chloride during hydrolysis. This difference is material in tablet and injectable processes because hydrogen chloride accelerates corrosion of 316L stainless steel and can react with acid-labile drug substances. Compared with N,O-bis(trimethylsilyl)trifluoroacetamide, HMDS leaves no fluoroacetamide by-product in the treated granule, but it requires stricter moisture control because the hydrolysis reaction is rapid. The selection of HMDS over aminosilane-based surface treatments is evaluated by forced degradation for drug substances containing primary or secondary amino groups, because aminosilanes can introduce pH shifts incompatible with acid-labile actives.

When the release specification of technical-grade HMDS is compared with pharmaceutical-grade and electronic-grade material, the relevant boundaries are chloride, water, assay, and residue on ignition. The following comparison is compiled from supplier safety data sheets and certificate-of-analysis summaries; specifications for individual lots may vary.

Under high-shear wet granulation, the replacement of technical-grade HMDS with pharmaceutical-grade material is justified when the drug product has an ion-sensitive or acid-labile active molecule. The lower chloride specification prevents pitting corrosion in the granulator barrel after extended campaigns; the lower residue on ignition reduces transfer of nonvolatile organosilicon oligomers to the tablet core. In injectable vial processing, the same specification set is applied to primary packaging surfaces because electronic-grade material does not carry the pharmacopoeial residual solvent and elemental impurity test data required by ICH Q3D. Operational boundary: HMDS is introduced only after granule or vial moisture is below the specified threshold, all contacting surfaces are dry, and vessels are inerted to avoid ammonia evolution and loss of silylating capacity. For oral liquid and injectable formulations, the material is used as a manufacturing aid; it is not a component of the final solution or suspension.